Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

US9896434B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Lothar Schwink · Stadtallendorf, DE
• Christian Buning · Frankfurt am Main, DE
• Heiner Glombik · Hofheim, DE
• Matthias Gossel · Frankfurt am Main, DE
• Dieter Kadereit · Kelkheim, DE
• Nis Halland · Frankfurt am Main, DE
• Matthias Lohmann · Frankfurt am Main, DE
• Christoph Pöverlein · Frankfurt am Main, DE
• Kurt Ritter · Heidelberg, DE

Key dates

• Filing date: Apr 2, 2015
• Grant date: Feb 20, 2018
• Expiry date: Apr 2, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D207/273
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.